Endolymphatic therapy for chronic lymphovenous insufficiency complicated by trophic ulcers

Resumen

This article puts forward a method of endolymphaticadministration of immunostimulants,which directly affect the immunocompetentcells in lymph nodes so that their effect is much morepronounced. From this perspective, selenase is especiallypromising, as it not only shows a pronounced antioxidanteffect, but also an immunomodulating effect, whichmeans that it normalizes the status of different parts ofthe immune system, as well as the immunological tolerance.This enables endolymphatic administration of drug.This article evaluates the treatment of trophic ulcers ofthe lower extremities in 58 patients. The main group consistedof 30 patients at mean age 68.2 (14 or 46.7%,were men; 16, or 53.3%, were women). The referencegroup consisted of 28 patients at mean age 67.9 (12 or43%, were men; 16 or 57%, were women). Trials provedthat endolymphatic therapy is a selective targeting on thesite of pathology and the main routes of lymphatic drainage.Endolymphatic therapy improves the short-terms andlong-term outcomes of patients with trophic ulcers thatappeared on the background of lymphovenous problems.Clinical trial has shown that trophic ulcers were healingbetter in the main group. The best outcomes were displayedby 19 (63.3%) patients from the main group and13 (46.4%) patients from the reference group. This articlereports on originally designed program of complex treatmentfor patients with trophic ulcers that appeared on thebackground of lymphovenous insufficiency of the lowerextremities, which implies the infusion of meronem, selenaseand sulodexide as endolymphatic therapy. Designedprogram was proved to be effective.